Consequences of Cannabinoid and Monoaminergic System Disruption in a Mouse Model of Autism Spectrum Disorders

E-ISSN： 1875-6190|9|1|209-214

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.9, Iss.1, 2011-03, pp. : 209-214

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Melatonin in Autism Spectrum Disorders

Current Clinical Pharmacology, Vol. 9, Iss. 4, 2014-11 ,pp. : 326-334

Bentham Science Publishers

Access to resources Recommend Favorite

New directions in the treatment of autism spectrum disorders from animal model research

By Chadman Kathryn K Guariglia Sara R Yoo Jiyeon Helen

Expert Opinion on Drug Discovery, Vol. 7, Iss. 5, 2012-05 ,pp. : 407-416

Informa Healthcare

Access to resources Recommend Favorite

The status of pharmacotherapy for autism spectrum disorders

By Myers Scott M

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1579-1603

Informa Healthcare

Access to resources Recommend Favorite

Autism spectrum disorders: emerging pharmacotherapy

By Bostic Jeff Q King Bryan H

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 3, 2005-08 ,pp. : 521-536

Informa Healthcare

Access to resources Recommend Favorite

The Role of Oxytocin in Autism Spectrum Disorders

By Canitano Roberto Scandurra Valeria

Current Psychopharmacology, Vol. 1, Iss. 2, 2012-05 ,pp. : 178-182

Bentham Science Publishers

Access to resources Recommend Favorite